MedPath

Ebronucimab

Generic Name
Ebronucimab
Brand Names
伊喜宁
Clinical Trials
Related News

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

Phase 1
Not yet recruiting
Conditions
Healthy Subjects (HS)
Interventions
First Posted Date
2024-10-15
Last Posted Date
2024-10-15
Lead Sponsor
Akeso
Target Recruit Count
180
Registration Number
NCT06641388
Locations
🇨🇳

The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Phase 3
Completed
Conditions
Hyperlipidemia
Interventions
Drug: Placebo
First Posted Date
2022-03-02
Last Posted Date
2025-03-06
Lead Sponsor
Akeso
Target Recruit Count
246
Registration Number
NCT05260411
Locations
🇨🇳

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

🇨🇳

Zhongshan Hospital, Fudan Hospital, Shanghai, China

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Phase 3
Completed
Conditions
Hyperlipidemia
Interventions
Drug: Placebo
First Posted Date
2022-02-24
Last Posted Date
2025-03-06
Lead Sponsor
Akeso
Target Recruit Count
464
Registration Number
NCT05255094
Locations
🇨🇳

Peking University First Hospital, Beijing, China

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Phase 3
Completed
Conditions
Hyperlipidemia
Interventions
Drug: Placebo
First Posted Date
2022-02-24
Last Posted Date
2025-02-28
Lead Sponsor
Akeso
Target Recruit Count
122
Registration Number
NCT05255458
Locations
🇨🇳

The Third Hospital of Nanchang, Nanchang, Jiangxi, China

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

Phase 2
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: Placebos
First Posted Date
2020-04-24
Last Posted Date
2023-03-02
Lead Sponsor
Akeso
Target Recruit Count
262
Registration Number
NCT04358432
Locations
🇨🇳

Zhong Shan Hosipital Fu Dan University, Shanghai, China

🇨🇳

Affiliated hospital of Guangdong medical university, Zhanjiang, China

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Phase 2
Completed
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Drug: Placebo
First Posted Date
2019-11-22
Last Posted Date
2023-03-02
Lead Sponsor
Akeso
Target Recruit Count
109
Registration Number
NCT04173793
Locations
🇨🇳

Beijing Anzhen Hospital, Beijing, Beijing, China

🇨🇳

Peking Union Medical College Hospital, Beijing, China

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

Phase 1
Completed
Conditions
Hypercholesterolaemia
Interventions
Drug: Placebo
First Posted Date
2019-11-19
Last Posted Date
2025-02-28
Lead Sponsor
Akeso
Target Recruit Count
32
Registration Number
NCT04169386
Locations
🇨🇳

Peking Union Medical College Hospital, Peking, China

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

Phase 2
Completed
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Drug: Statins
First Posted Date
2019-05-01
Last Posted Date
2023-03-02
Lead Sponsor
Akeso
Target Recruit Count
10
Registration Number
NCT03933293
Locations
🇨🇳

Beijing Anzhen Hospital, Beijing, Beijing, China

🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy